MeSH Review:
Neuroendocrine Tumors
de Vries,
Finardi,
Missale,
Jacobsen,
Gjermund Henriksen,
Weber,
Cavazza,
Joba,
Dilley,
Karwal,
Simon,
Lamberts,
Whelan,
Bavieri,
Arzt,
Renstrup,
Bushnell,
Westlin,
Maiorana,
Grübler,
Miller,
Paez-Pereda,
Lairmore,
Oberg,
Tolmachev,
Leticia Quintanilla-Martinez,
Matthias Miederer,
Välimäki,
Lamberts,
Bruskin,
Heufelder,
Sartori,
Piersall,
Fabbri,
Parker,
Fiasse,
Connolly,
Menda,
Reingard Senekowitsch-Schmidtke,
Brambilla,
Facciolongo,
Migaldi,
Morandi,
Hofland,
Ilona Mossbrugger,
Páez-Pereda,
Spano,
Kovalovsky,
Lubberink,
Rossi,
Hopfner,
Missale,
Losa,
Göke,
DeBenedetti,
Casali,
Widström,
Markus Essler,
Nobels,
Codignola,
Wymenga,
Pagotto,
Zehr,
Salmela,
Mutch,
Uhl,
Van Cutsem,
O'Dorisio,
Sigala,
Eriksson,
Schipper,
Lundqvist,
Stalla,
Zehnbauer,
Schmidt,
Stalla,
Behr,
Hofland,
Schirosi,
Carlisle,
Longo,
Bigiani,
Matthew H. Kulke,
Jason L. Hornick,
Christine Frauenhoffer,
Susanne Hooshmand,
David P. Ryan,
Peter C. Enzinger,
Jeffrey A. Meyerhardt,
Jeffrey W. Clark,
Keith Stuart,
Charles S. Fuchs,
Mark S. Redston,
Bert,
Marchioni,
Arnold,
Andrea Alke,
Bouterfa,
Béhé,
Sher,
Theodoropoulou,
- Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Harbour, J.W., Lai, S.L., Whang-Peng, J., Gazdar, A.F., Minna, J.D., Kaye, F.J. Science (1988)
- Retinoic acid prevents experimental Cushing syndrome. Páez-Pereda, M., Kovalovsky, D., Hopfner, U., Theodoropoulou, M., Pagotto, U., Uhl, E., Losa, M., Stalla, J., Grübler, Y., Missale, C., Arzt, E., Stalla, G.K. J. Clin. Invest. (2001)
- The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. Lawlor, E.R., Lim, J.F., Tao, W., Poremba, C., Chow, C.J., Kalousek, I.V., Kovar, H., MacDonald, T.J., Sorensen, P.H. Cancer Res. (1998)
- IA-2, a transmembrane protein tyrosine phosphatase, is expressed in human lung cancer cell lines with neuroendocrine phenotype. Xie, H., Notkins, A.L., Lan, M.S. Cancer Res. (1996)
- Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., Bigiani, N., Schirosi, L., Casali, C., Morandi, U., Facciolongo, N., Maiorana, A., Bavieri, M., Fabbri, L.M., Brambilla, E. J. Clin. Oncol. (2005)
- Peptide receptors as molecular targets for cancer diagnosis and therapy. Reubi, J.C. Endocr. Rev. (2003)
- The pathophysiological consequences of somatostatin receptor internalization and resistance. Hofland, L.J., Lamberts, S.W. Endocr. Rev. (2003)
- Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Deftos, L.J. Endocr. Rev. (1991)
- Neuroendocrine tumor markers. Lamberts, S.W., Hofland, L.J., Nobels, F.R. Frontiers in neuroendocrinology. (2001)
- Activated Raf-1 causes growth arrest in human small cell lung cancer cells. Ravi, R.K., Weber, E., McMahon, M., Williams, J.R., Baylin, S., Mal, A., Harter, M.L., Dillehay, L.E., Claudio, P.P., Giordano, A., Nelkin, B.D., Mabry, M. J. Clin. Invest. (1998)
- Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Wymenga, A.N., Eriksson, B., Salmela, P.I., Jacobsen, M.B., Van Cutsem, E.J., Fiasse, R.H., Välimäki, M.J., Renstrup, J., de Vries, E.G., Oberg, K.E. J. Clin. Oncol. (1999)
- Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. Andreyev, H.J., Scott-Mackie, P., Cunningham, D., Nicolson, V., Norman, A.R., Badve, S.S., Iveson, A., Nicolson, M.C. J. Clin. Oncol. (1995)
- Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Schipper, M.L., Weber, A., Béhé, M., Göke, R., Joba, W., Schmidt, H., Bert, T., Simon, B., Arnold, R., Heufelder, A.E., Behr, T.M. Cancer Res. (2003)
- Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors. Moattari, A.R., Deftos, L.J., Vinik, A.I. J. Clin. Endocrinol. Metab. (1989)
- Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. Nobels, F.R., Kwekkeboom, D.J., Coopmans, W., Schoenmakers, C.H., Lindemans, J., De Herder, W.W., Krenning, E.P., Bouillon, R., Lamberts, S.W. J. Clin. Endocrinol. Metab. (1997)
- Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., Essler, M. Clin. Cancer Res. (2008)
- O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Kulke, M.H., Hornick, J.L., Frauenhoffer, C., Hooshmand, S., Ryan, D.P., Enzinger, P.C., Meyerhardt, J.A., Clark, J.W., Stuart, K., Fuchs, C.S., Redston, M.S. Clin. Cancer Res. (2009)
- IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Vitale, G., de Herder, W.W., van Koetsveld, P.M., Waaijers, M., Schoordijk, W., Croze, E., Colao, A., Lamberts, S.W., Hofland, L.J. Cancer Res. (2006)
- Differential glucocorticoid regulation of glucagon gene expression in cell lines derived from rat and hamster islet cell tumors. Wang, C., Campos, R.V., Stobie, K.M., Brubaker, P.L., Drucker, D.J. Cancer Res. (1991)
- Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Muscarella, P., Melvin, W.S., Fisher, W.E., Foor, J., Ellison, E.C., Herman, J.G., Schirmer, W.J., Hitchcock, C.L., DeYoung, B.R., Weghorst, C.M. Cancer Res. (1998)
- Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice. Nikitin, A.Y., Liu, C.Y., Flesken-Nikitin, A., Chen, C.F., Chen, P.L., Lee, W.H. Cancer Res. (2002)
- Expression of phosphoprotein p19 in brain, testis, and neuroendocrine tumor cells. Developmental regulation in rat brain. Schubart, U.K. J. Biol. Chem. (1988)
- Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Missale, C., Codignola, A., Sigala, S., Finardi, A., Paez-Pereda, M., Sher, E., Spano, P.F. Proc. Natl. Acad. Sci. U.S.A. (1998)
- Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion. Colombo, B., Longhi, R., Marinzi, C., Magni, F., Cattaneo, A., Yoo, S.H., Curnis, F., Corti, A. J. Biol. Chem. (2002)
- Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Lairmore, T.C., Piersall, L.D., DeBenedetti, M.K., Dilley, W.G., Mutch, M.G., Whelan, A.J., Zehnbauer, B. Ann. Surg. (2004)
- Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. Bushnell, D., O'Dorisio, T., Menda, Y., Carlisle, T., Zehr, P., Connolly, M., Karwal, M., Miller, S., Parker, S., Bouterfa, H. J. Nucl. Med. (2003)
- The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. de Keyzer, Y., Lenne, F., Auzan, C., Jégou, S., René, P., Vaudry, H., Kuhn, J.M., Luton, J.P., Clauser, E., Bertagna, X. J. Clin. Invest. (1996)
- Multiple leiomyomas of the esophagus, lung, and uterus in multiple endocrine neoplasia type 1. McKeeby, J.L., Li, X., Zhuang, Z., Vortmeyer, A.O., Huang, S., Pirner, M., Skarulis, M.C., James-Newton, L., Marx, S.J., Lubensky, I.A. Am. J. Pathol. (2001)
- The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. Korbonits, M., Bustin, S.A., Kojima, M., Jordan, S., Adams, E.F., Lowe, D.G., Kangawa, K., Grossman, A.B. J. Clin. Endocrinol. Metab. (2001)
- Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. Grouzmann, E., Comoy, E., Bohuon, C. J. Clin. Endocrinol. Metab. (1989)
- Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors. Marsh, D.J., Zheng, Z., Arnold, A., Andrew, S.D., Learoyd, D., Frilling, A., Komminoth, P., Neumann, H.P., Ponder, B.A., Rollins, B.J., Shapiro, G.I., Robinson, B.G., Mulligan, L.M., Eng, C. J. Clin. Endocrinol. Metab. (1997)
- Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Scherübl, H., Bäder, M., Fett, U., Hamm, B., Schmidt-Gayk, H., Koppenhagen, K., Dop, F.J., Riecken, E.O., Wiedenmann, B. Gastroenterology (1993)
- Gastrin-releasing peptide, a mammalian analog of bombesin, is present in human neuroendocrine lung tumors. Bostwick, D.G., Roth, K.A., Evans, C.J., Barchas, J.D., Bensch, K.G. Am. J. Pathol. (1984)
- Somatostatin acts by inhibiting the cyclic 3',5'-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Tentler, J.J., Hadcock, J.R., Gutierrez-Hartmann, A. Mol. Endocrinol. (1997)
- Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. Virgolini, I., Szilvasi, I., Kurtaran, A., Angelberger, P., Raderer, M., Havlik, E., Vorbeck, F., Bischof, C., Leimer, M., Dorner, G., Kletter, K., Niederle, B., Scheithauer, W., Smith-Jones, P. J. Nucl. Med. (1998)
- 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. Lubberink, M., Tolmachev, V., Widström, C., Bruskin, A., Lundqvist, H., Westlin, J.E. J. Nucl. Med. (2002)